Steigende Kosten für Arzneimittel und Gesundheit stellen ein Problem für die sozialen Sicherungssysteme dar, sind aber geringer als oft angenommen. Was treibt die Kosten in die Höhe? Wie können Arzneimittelinnovationen auch in Zukunft noch bezahlbar bleiben?
This is a preview of subscription content, log in via an institution to check access.
Literatur
Robert Koch-Institut (2016) Bericht zum Krebsgeschehen in Deutschland, pp 1–274, Robert Koch Institut, Berlin.
Schwabe U and Paffrath D (2016) Arzneiverordnungen 2015 im Überblick, in Arzneiverordnungsreport 2016 (Schwabe U and Paffrath D eds) pp 3–27, Springer, Heidelberg.
Scannell JW (2015) Four reasons drugs are expensive, of which two are false. http://onforb.es/1ZdvQbc
Greer JA, Pirl WF, Jackson VA, Muzikansky A, Lennes IT, Heist RS, Gallagher ER and Temel JS (2012) Effect of early palliative care on chemotherapy use and end-of-life care in patients with metastatic non-small-cell lung cancer. J Clin Oncol 30:394–400.
Maxmen A (2016) Busting the billion-dollar myth: how to slash the cost of drug development. Nature 536:388–390.
Scannell JW, Blanckley A, Boldon H and Warrington B (2012) Diagnosing the decline in pharmaceutical R&D efficiency. Nature Reviews: Drug Discovery 11:191–200.
Herper M (2012) The truly staggering cost of inventing new drugs. http://onforb.es/yNffHT
Yildirim O, Gottwald M, Schüler P and Michel MC (2016) Opportunities and challenges for drug development: public-private partnerships, adaptive drug design and big data. Front Pharmacol 7:461.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Michel, M.C. Sind neue Medikamente zu teuer?. MMW - Fortschritte der Medizin 159, 65–67 (2017). https://doi.org/10.1007/s15006-017-9487-7
Published:
Issue Date:
DOI: https://doi.org/10.1007/s15006-017-9487-7